Indian Vaccine Market Report by Monovalent and Combined Vaccines (BCG, HIB, Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, HPV, Hexavalent, Dengue Vaccines) 2024-2032

Indian Vaccine Market Report by Monovalent and Combined Vaccines (BCG, HIB, Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, HPV, Hexavalent, Dengue Vaccines) 2024-2032

Report Format: PDF+Excel | Report ID: SR112025A554

Market Overview: 

The Indian vaccine market size is expected to exhibit a growth rate (CAGR) of 12.3% during 2024-2032.

Report Attribute
Key Statistics
Base Year  2023
Forecast Years  2024-2032
Historical Years 
2018-2023
Market Growth Rate 2024-2032
12.3%


A vaccine is a biological substance that is developed to boost the immune system while protecting against bacterial and viral diseases. It comprises live attenuated, inactivated, toxoid, mRNA, viral vector, and subunit, recombinant, polysaccharide, and conjugate vaccines. It is consumed orally, by aerosol, or through injections to prevent several diseases, such as measles, polio, tetanus, influenza, rabies, and whooping cough. In addition, it stimulates the body to make antibodies against antigens or pathogens. At present, there is a rise in the production of vaccines in India due to technological advancements and the increasing number of cold chain storage facilities.

Indian Vaccine Market Trends:

The Government of India (GOI) is currently launching various campaigns, such as the Universal Immunization Program (UIP), to increase immunization coverage against vaccine-preventable diseases in the country. This, along with the growing health awareness among the masses, represents one of the key factors driving the market in India. Moreover, the rising export of generic medicines in India that imitates brand-name drugs in effect, strength, doses, qualities, forms, administration, and safety is contributing to the growth of the market. In addition, there is an increase in the number of private companies that are producing cost-effective vaccines and investing in their distribution throughout India. This, coupled with the burgeoning healthcare industry, is strengthening the growth of the market in the country. Besides this, key market players are extensively investing in research and development (R&D) activities to introduce new and enhanced vaccines. They are also focusing on developing innovative ways to distribute vaccines effectively within the country and international markets, which is catalyzing the demand for Indian vaccines. Other factors propelling the market growth are the increasing population, inflating income levels of individuals, improving existing vaccine infrastructure, the expanding logistics industry, and the growing participation of non-governmental organizations (NGOs).

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the Indian vaccine market report, along with forecasts for the period 2024-2032. Our report has categorized the market based on monovalent and combined vaccines.

Breakup by Monovalent and Combined Vaccines:

Indian Vaccine Market

  • BCG 
  • HIB 
  • Influenza 
  • Varicella 
  • Typhoid 
  • Japanese Encephalitis
  • Measles 
  • Tetanus Toxoid 
  • Hepatitis A 
  • Rubella 
  • Diphtheria 
  • Tetanus, and Pertussis (DPT) 
  • Oral Polio Vaccine (OPV) 
  • MMR 
  • Rotavirus 
  • Hepatitis B 
  • Pneumococcal 
  • Meningococcal 
  • Rabies
  • HPV
  • Hexavalent
  • Dengue vaccines

The Focus of the Analysis for Each Vaccine

  • Vaccine Overview 
  • Historical and Current Market Trends
  • Market Breakup by Prescriber
  • Market Breakup by Public and Private Sector
  • Market Outlook

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila and MSD.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units Million, INR Million
Scope of the Report
Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Monovalent and Combined Vaccines
Monovalent and Combined Vaccines Covered BCG, HIB, Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, HPV, Hexavalent, Dengue vaccines 
Companies Covered GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila and MSD.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

We expect the Indian vaccine market to exhibit a CAGR of 12.3% during 2024-2032.

The rising prevalence of various infectious diseases, such as polio, measles, influenza, etc., along with the introduction of improved vaccines by pharmaceutical companies for fatal medical ailments, is primarily driving the Indian vaccine market.

The sudden outbreak of the COVID-19 pandemic has led to the growing utilization of novel vaccines across clinics, hospitals, and vaccination centers for immunization procedures to combat the spread of the coronavirus infection across the nation.

Based on the monovalent and combined vaccines, the Indian vaccine market can be bifurcated into BCG, HIB, influenza, varicella, typhoid, Japanese encephalitis, measles, tetanus toxoid, hepatitis A, rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, rotavirus, hepatitis B, pneumococcal, meningococcal, rabies, HPV, hexavalent, and dengue vaccines. Currently, pneumococcal holds the majority of the total market share.

Some of the major players in the Indian vaccine market include GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila, and MSD.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Indian Vaccine Market Report by Monovalent and Combined Vaccines (BCG, HIB, Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, HPV, Hexavalent, Dengue Vaccines) 2024-2032
Purchase Options
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials